Sienna Biopharmaceuticals, Inc., a Westlake Village, Calif.-based development stage company focused on aesthetics and medical dermatology, closes $34m Series A financing.
The round was led by Arch Venture Partners with participation from Altitude Life Science Ventures, Partner Fund Management, and Venvest Capital, as well as direct investment from several prominent aesthetics and medical dermatology industry professionals.
The company intends to use the funds to advance its technology and further its efforts to build a pipeline of early- to late-stage novel assets.
Led by Frederick C. Beddingfield III, M.D., Ph.D., as President and CEO, and Keith Leonard, as Executive Chairman, Sienna Biopharmaceutical aims to bring to market innovative new products that have the potential to improve patient outcomes and advance the practice of medicine in aesthetics and medical dermatology. Its lead proprietary technology, Silver Plasmonic Therapy (SPT), has promising applications for acne and permanent hair removal. Clinical trials are already underway and the company is evaluating additional potential indications.